# Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Source: https://onco.cc/trials/nct03384238/  
OnCo record `nct03384238` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of panitumumab in pancreatic cancer, run by George Poultsides, now recruiting.

## Summary

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery is a phase 1/2, interventional study registered as NCT03384238 by George Poultsides, with a registry enrolment figure of 27 participants, started 2018-02-07 and due to reach its primary completion in 2027-03. Interventions recorded: Fluorescence Imaging; Panitumumab; Panitumumab-IRDye800. Conditions listed: Pancreatic Adenocarcinoma. Primary outcome: Tumor to background ratio (TBR). Pancreatic eligibility wording from the registry: "* Clinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT03384238
- Phase: 1/2
- Setting: A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Pancreas Cancer During Surgical Procedures
- Sponsor: George Poultsides
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT03384238: https://clinicaltrials.gov/study/NCT03384238

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- drugs: [Panitumumab](https://onco.cc/drugs/panitumumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03384238.json